PRISM MediaWire

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

-Significant unmet need for regulated product in $2B US testing market--Opportunity for expedited pathway for kitted product in development-

6 December 2023

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Upgrading at Ecuador Center (GKCE) with State-of-the-Art Gamma Knife ICON

Upgrade of Gamma Knife® 4C with NEW Elekta ICON for most precise and accurate treatment of Intracranial cancers and other indications

28 November 2023

SS Innovations International SSi Mantra Robotic Surgical System Crosses 500 Successful Procedure Milestone

Company Founder and Chairman, Dr. Sudhir P. Srivastava performed complex heart surgery, while simultaneously, Dr. Sudhir K. Rawal, Medical Director for Rajiv Gandhi Cancer Institute, performed complex Urology Oncology surgery, marking 500 surgery milestone using the SSi ...

27 November 2023

PRISM MediaWire - Weekly Press Resume - Nov. 13 to Nov. 17, 2023

PRISM MediaWire

17 November 2023

PRISM MarketView Spotlights Significant Market Opportunities in Global Health with Launch of Emerging Public Health Index

NEW YORK, NY, November 14, 2023 - PRISM MediaWire - PRISM MarketView, a leader within the financial markets and news community, has debuted its PRISM Emerging Public Health Index.

14 November 2023

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT

14 November 2023

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” ~Dr. Michael Chancellor, Chief Medical Officer at Lipel...

10 November 2023

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024--Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET-

9 November 2023

BioStem Technologies Awarded Q Code for VENDAJE AC®

“Securing the CMS Q code for our VENDAJE AC® tissue allograft marks yet another win for BioStem Technologies and ensures broader access to another top-tier wound care product within our portfolio.” ~BioStem Technologies CEO, Jason Matuszewski

8 November 2023

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

POMPANO BEACH, FLORIDA, November 8, 2023 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announ...

8 November 2023